Antonio Dans
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Antonio Dans has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Leonila F. Dans
Program on Health Systems Development - Philippine Primary Care Studies, Center for Integrative and Development Studies, University of the Philippines Diliman, Quezon City, Philippines
7 shared publications - Carol Stephanie Chua Tan-Lim
Department of Clinical Epidemiology, College of Medicine, University of the Philippines Manila, Manila, Philippines
6 shared publications - Anton Elepaño
Nuffield Department of Primary Care Health Sciences, Medical Sciences division, University of Oxford, Oxford, United Kingdom
3 shared publications - Josephine Sanchez
Center for Integrative and Development Studies, University of the Philippines Diliman, Quezon City, Philippines
3 shared publications - Noleen Marie C. Fabian
Center for Integrative and Development Studies, University of the Philippines Diliman, Quezon City, Philippines
3 shared publications Salim Yusuf
Population Health Research Institute, Hamilton Health Sciences, McMaster University , DBCVSRI, 20 Copeland Avenue, Hamilton, ON L8L 2X2, Canada
3 shared publications
Latest Publications
- Open Access
- 31 August 2026
- Published by University of the Philippines Manila in Acta Medica Philippina
- Vol. 60 (16) , 7-16
Impact of Primary Care Benefits on Outpatient Health Care Utilization and Estimated Out-of-Pocket Expenses: A Follow-up Pre-post Study of Three Primary Care Sites in the Philippines
Background. Health inequity is a prevailing issue in the Philippines. Universal health care (UHC) aims to provide equitable access to healthcare services and protection from financial risk for all Filipinos. The Philippine Primary Care Studies (PPCS) evaluated the impact of interventions to improve primary care in an urban, rural, and remote area in the country, which represented communities with higher, lower, and least baseline resources for health care, respectively. We previously measured healthcare utilization and change in out-of-pocket (OOP) expenses for outpatient services from baseline to one year after implementation of interventions. Objective. This is a follow-up study that measured the same outcomes until funding for the interventions was depleted. Methods. The interventions to strengthen the primary care system included equal per capita health financing in all three areas, establishment of an electronic health record system, healthcare worker training, and early community engagement. Other context-specific interventions were also implemented in the rural and remote sites. We evaluated healthcare utilization (measured as the total number of ambulatory consultations per month) and OOP expenses (estimated through community surveys performed at baseline and yearly thereafter). These outcomes were measured at baseline prior to implementation of interventions, during the first year of implementation when full funding was available, in the second year of implementation when partial funding was available, and at the third or fourth year of implementation when funding ended. Results. Improvements in primary care had the most impact on the rural site, having the highest number of cumulative ambulatory consults and the lowest out-of-pocket expenses per study year. It had the least impact on the urban site, while the remote site generally had modest improvements. Conclusion. Policies and interventions to improve primary care may inadvertently aggravate existing inequities, especially in remote areas. Rather than equal distribution, funding must be allocated according to need, and interventions must be contextualized to local settings, if UHC is to successfully reduce inequities in healthcare access in the country.
- 31 August 2026
- Published by University of the Philippines Manila in Acta Medica Philippina
- Vol. 60 (16) , 7-16
Open AccessImpact of Primary Care Benefits on Outpatient Health Care Utilization and Estimated Out-of-Pocket Expenses: A Follow-up Pre-post Study of Three Primary Care Sites in the Philippines
Background. Health inequity is a prevailing issue in the Philippines. Universal health care (UHC) aims to provide equitable access to healthcare services and protection from financial risk for all Filipinos. The Philippine Primary Care Studies (PPCS) evaluated the impact of interventions to improve primary care in an urban, rural, and remote area in the country, which represented communities with higher, lower, and least baseline resources for health care, respectively. We previously measured healthcare utilization and change in out-of-pocket (OOP) expenses for outpatient services from baseline to one year after implementation of interventions. Objective. This is a follow-up study that measured the same outcomes until funding for the interventions was depleted. Methods. The interventions to strengthen the primary care system included equal per capita health financing in all three areas, establishment of an electronic health record system, healthcare worker training, and early community engagement. Other context-specific interventions were also implemented in the rural and remote sites. We evaluated healthcare utilization (measured as the total number of ambulatory consultations per month) and OOP expenses (estimated through community surveys performed at baseline and yearly thereafter). These outcomes were measured at baseline prior to implementation of interventions, during the first year of implementation when full funding was available, in the second year of implementation when partial funding was available, and at the third or fourth year of implementation when funding ended. Results. Improvements in primary care had the most impact on the rural site, having the highest number of cumulative ambulatory consults and the lowest out-of-pocket expenses per study year. It had the least impact on the urban site, while the remote site generally had modest improvements. Conclusion. Policies and interventions to improve primary care may inadvertently aggravate existing inequities, especially in remote areas. Rather than equal distribution, funding must be allocated according to need, and interventions must be contextualized to local settings, if UHC is to successfully reduce inequities in healthcare access in the country.
- Open Access
- 16 February 2026
- Published by Springer Nature in BMC Primary Care
- Vol. 27 (1)
Quality-of-care of Filipino patients with hypertension in primary care settings
Hypertension is one of the most common conditions seen in the Philippine primary care setting. Adequate quality of care provided in accordance with clinica
- 16 February 2026
- Published by Springer Nature in BMC Primary Care
- Vol. 27 (1)
Open AccessQuality-of-care of Filipino patients with hypertension in primary care settings
Hypertension is one of the most common conditions seen in the Philippine primary care setting. Adequate quality of care provided in accordance with clinica
- Open Access
- 7 January 2026
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 10 (1) , e69874
Adoption of an Electronic Decision Support Tool for Capacity Building of Community Health Workers: Mixed Methods Study
Background: Complimentary subscriptions to UpToDate, a decision support tool, were provided to community health workers (CHWs) in rural and remote primary care sites as part of a government-funded health system research program. A feasibility evaluation conducted after the first year of implementation showed that UpToDate was acceptable among CHWs despite infrastructural barriers. Objective: This follow-up study evaluated the longitudinal adoption of UpToDate among CHWs and examined how sociocultural, political, and environmental factors influenced its use. Drawing on the nonadoption, abandonment, scale-up, spread, and sustainability framework, this study aimed to understand not only use patterns but also broader challenges to scale-up, spread, and sustainability in a complex health system. Methods: An explanatory mixed methods design was used combining analysis of use and program activity logs; program reports; and focus groups with CHWs, health care professionals, and program implementers. Quantitative analysis of use logs (March 2021 to September 2023) compared adoption over time by using descriptive statistics, CIs, and chi-square tests. Qualitative data came from the reanalysis of previous focus group transcripts and program reports and from a new focus group with program implementers. Reflexive thematic analysis was used to interpret how CHWs and implementers perceived and used the tool, and findings were integrated to explain quantitative trends. Results: Use of UpToDate was modest and declined over time. Monthly active use among CHWs and midwives fell substantially from 3.57% (97/2720 person-months) in 2021 to 1.07% (37/3456) in 2022 and remained low at 1.50% (39/2592) up to 2023, with markedly higher engagement in the rural site than in the remote site. Peaks in use coincided with program activities, whereas prolonged troughs followed typhoons, power outages, and other disruptions. Log data showed that users primarily consulted patient education articles rather than clinician-oriented decision tools. Qualitative analyses revealed that CHWs appropriated UpToDate as a learning aid and source of professional credibility. Structural shocks, heavy workloads, language barriers, and limited device access constrained individual use, and communal practices (shared devices and learning activities) meant that meaningful engagement often went unrecorded in vendor metrics. Conclusions: Our findings show that acceptability does not guarantee sustained use and that adoption cannot be captured fully by log-in counts. UpToDate’s value for CHWs lay in how it was domesticated as a tool for building capacity and professional credibility, not in its intended function as a decision aid used at the point of care. Therefore, evaluations of digital health tools should incorporate indicators of learning and social capital alongside use metrics. Policymakers should recognize that infrastructural fragility and communal adaptation shape digital health uptake. Embedding tools into ongoing training and peer learning structures, providing offline and multilingual support, and investing in resilience planning will be crucial for meaningful scale-up and sustainability.
- 7 January 2026
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 10 (1) , e69874
Open AccessAdoption of an Electronic Decision Support Tool for Capacity Building of Community Health Workers: Mixed Methods Study
Background: Complimentary subscriptions to UpToDate, a decision support tool, were provided to community health workers (CHWs) in rural and remote primary care sites as part of a government-funded health system research program. A feasibility evaluation conducted after the first year of implementation showed that UpToDate was acceptable among CHWs despite infrastructural barriers. Objective: This follow-up study evaluated the longitudinal adoption of UpToDate among CHWs and examined how sociocultural, political, and environmental factors influenced its use. Drawing on the nonadoption, abandonment, scale-up, spread, and sustainability framework, this study aimed to understand not only use patterns but also broader challenges to scale-up, spread, and sustainability in a complex health system. Methods: An explanatory mixed methods design was used combining analysis of use and program activity logs; program reports; and focus groups with CHWs, health care professionals, and program implementers. Quantitative analysis of use logs (March 2021 to September 2023) compared adoption over time by using descriptive statistics, CIs, and chi-square tests. Qualitative data came from the reanalysis of previous focus group transcripts and program reports and from a new focus group with program implementers. Reflexive thematic analysis was used to interpret how CHWs and implementers perceived and used the tool, and findings were integrated to explain quantitative trends. Results: Use of UpToDate was modest and declined over time. Monthly active use among CHWs and midwives fell substantially from 3.57% (97/2720 person-months) in 2021 to 1.07% (37/3456) in 2022 and remained low at 1.50% (39/2592) up to 2023, with markedly higher engagement in the rural site than in the remote site. Peaks in use coincided with program activities, whereas prolonged troughs followed typhoons, power outages, and other disruptions. Log data showed that users primarily consulted patient education articles rather than clinician-oriented decision tools. Qualitative analyses revealed that CHWs appropriated UpToDate as a learning aid and source of professional credibility. Structural shocks, heavy workloads, language barriers, and limited device access constrained individual use, and communal practices (shared devices and learning activities) meant that meaningful engagement often went unrecorded in vendor metrics. Conclusions: Our findings show that acceptability does not guarantee sustained use and that adoption cannot be captured fully by log-in counts. UpToDate’s value for CHWs lay in how it was domesticated as a tool for building capacity and professional credibility, not in its intended function as a decision aid used at the point of care. Therefore, evaluations of digital health tools should incorporate indicators of learning and social capital alongside use metrics. Policymakers should recognize that infrastructural fragility and communal adaptation shape digital health uptake. Embedding tools into ongoing training and peer learning structures, providing offline and multilingual support, and investing in resilience planning will be crucial for meaningful scale-up and sustainability.
- Open Access
- 15 July 2025
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 13 (1) , e63036
Implementing Electronic Health Records in Philippine Primary Care Settings: Mixed-Methods Pilot Study
Background: Between 2020 and 2022, the Philippine Primary Care Studies program, a government-funded initiative supporting universal health care implementation, piloted two electronic health records (EHR) systems across urban, rural, and remote primary care sites. Objective: The study aimed to evaluate the implementation of two EHR systems in diverse primary care settings in the Philippines over a three-year period. Methods: This implementation study used an explanatory mixed methods design. Two EHR systems were deployed: an Open Medical Records System (OpenMRS)-based platform in 2016, and a Microsoft-based system in 2021. Both systems integrated clinical documentation, pharmacy, laboratory, and reporting modules. Implementation strategies included training workshops and materials, iterative user feedback loops, and infrastructure cofinancing with local governments. Surveys were administered yearly to all end users. The primary outcome was behavioral intention to use the system. Quantitative data were supplemented by inductive content analysis of qualitative responses to explain observed trends. Results: A total of 351 survey responses were collected from 2020 to 2022. In 2020, the intention to use the OpenMRS-based EHR was high across all sites. By 2022, following the launch of the Microsoft-based EHR, acceptability declined significantly among doctors and administrative staff, particularly at the urban site. In contrast, the remote site which retained the OpenMRS-based system maintained high acceptability levels. Qualitative findings revealed that while the new EHR system provided a more privacy-focused design, users preferred a cross-platform EHR to allow more flexible access to patient data. At the rural site where the EHR was used to facilitate task-shifting among nurses involved in clinical management, users were less impacted by this shift. Conclusions: The disparities in EHR acceptability across urban, rural, and remote sites were influenced by contextual, technical, and demographic factors. The decline in acceptability following the EHR system transition highlights the importance of implementation strategies that reflect the specific needs and capacities of each setting. These findings offer practical insights for adapting EHR systems to diverse primary care contexts.
- 15 July 2025
- Published by JMIR Publications Inc. in JMIR Medical Informatics
- Vol. 13 (1) , e63036
Open AccessImplementing Electronic Health Records in Philippine Primary Care Settings: Mixed-Methods Pilot Study
Background: Between 2020 and 2022, the Philippine Primary Care Studies program, a government-funded initiative supporting universal health care implementation, piloted two electronic health records (EHR) systems across urban, rural, and remote primary care sites. Objective: The study aimed to evaluate the implementation of two EHR systems in diverse primary care settings in the Philippines over a three-year period. Methods: This implementation study used an explanatory mixed methods design. Two EHR systems were deployed: an Open Medical Records System (OpenMRS)-based platform in 2016, and a Microsoft-based system in 2021. Both systems integrated clinical documentation, pharmacy, laboratory, and reporting modules. Implementation strategies included training workshops and materials, iterative user feedback loops, and infrastructure cofinancing with local governments. Surveys were administered yearly to all end users. The primary outcome was behavioral intention to use the system. Quantitative data were supplemented by inductive content analysis of qualitative responses to explain observed trends. Results: A total of 351 survey responses were collected from 2020 to 2022. In 2020, the intention to use the OpenMRS-based EHR was high across all sites. By 2022, following the launch of the Microsoft-based EHR, acceptability declined significantly among doctors and administrative staff, particularly at the urban site. In contrast, the remote site which retained the OpenMRS-based system maintained high acceptability levels. Qualitative findings revealed that while the new EHR system provided a more privacy-focused design, users preferred a cross-platform EHR to allow more flexible access to patient data. At the rural site where the EHR was used to facilitate task-shifting among nurses involved in clinical management, users were less impacted by this shift. Conclusions: The disparities in EHR acceptability across urban, rural, and remote sites were influenced by contextual, technical, and demographic factors. The decline in acceptability following the EHR system transition highlights the importance of implementation strategies that reflect the specific needs and capacities of each setting. These findings offer practical insights for adapting EHR systems to diverse primary care contexts.
- Open Access
- 10 December 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Adoption of an Electronic Decision Support Tool for Capacity Building of Community Health Workers: Mixed Methods Study (Preprint)
BACKGROUND Complimentary subscriptions to UpToDate, a decision support tool, were provided to community health workers (CHWs) in rural and remote primary care sites as part of a government-funded health system research program. A feasibility evaluation conducted after the first year of implementation showed that UpToDate was acceptable among CHWs despite infrastructural barriers. OBJECTIVE This follow-up study evaluated the longitudinal adoption of UpToDate among CHWs and examined how sociocultural, political, and environmental factors influenced its use. Drawing on the nonadoption, abandonment, scale-up, spread, and sustainability framework, this study aimed to understand not only use patterns but also broader challenges to scale-up, spread, and sustainability in a complex health system. METHODS An explanatory mixed methods design was used combining analysis of use and program activity logs; program reports; and focus groups with CHWs, health care professionals, and program implementers. Quantitative analysis of use logs (March 2021 to September 2023) compared adoption over time by using descriptive statistics, CIs, and chi-square tests. Qualitative data came from the reanalysis of previous focus group transcripts and program reports and from a new focus group with program implementers. Reflexive thematic analysis was used to interpret how CHWs and implementers perceived and used the tool, and findings were integrated to explain quantitative trends. RESULTS Use of UpToDate was modest and declined over time. Monthly active use among CHWs and midwives fell substantially from 3.57% (97/2720 person-months) in 2021 to 1.07% (37/3456) in 2022 and remained low at 1.50% (39/2592) up to 2023, with markedly higher engagement in the rural site than in the remote site. Peaks in use coincided with program activities, whereas prolonged troughs followed typhoons, power outages, and other disruptions. Log data showed that users primarily consulted patient education articles rather than clinician-oriented decision tools. Qualitative analyses revealed that CHWs appropriated UpToDate as a learning aid and source of professional credibility. Structural shocks, heavy workloads, language barriers, and limited device access constrained individual use, and communal practices (shared devices and learning activities) meant that meaningful engagement often went unrecorded in vendor metrics. CONCLUSIONS Our findings show that acceptability does not guarantee sustained use and that adoption cannot be captured fully by log-in counts. UpToDate’s value for CHWs lay in how it was domesticated as a tool for building capacity and professional credibility, not in its intended function as a decision aid used at the point of care. Therefore, evaluations of digital health tools should incorporate indicators of learning and social capital alongside use metrics. Policymakers should recognize that infrastructural fragility and communal adaptation shape digital health uptake. Embedding tools into ongoing training and peer learning structures, providing offline and multilingual support, and investing in resilience planning will be crucial for meaningful scale-up and sustainability.
- 10 December 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessAdoption of an Electronic Decision Support Tool for Capacity Building of Community Health Workers: Mixed Methods Study (Preprint)
BACKGROUND Complimentary subscriptions to UpToDate, a decision support tool, were provided to community health workers (CHWs) in rural and remote primary care sites as part of a government-funded health system research program. A feasibility evaluation conducted after the first year of implementation showed that UpToDate was acceptable among CHWs despite infrastructural barriers. OBJECTIVE This follow-up study evaluated the longitudinal adoption of UpToDate among CHWs and examined how sociocultural, political, and environmental factors influenced its use. Drawing on the nonadoption, abandonment, scale-up, spread, and sustainability framework, this study aimed to understand not only use patterns but also broader challenges to scale-up, spread, and sustainability in a complex health system. METHODS An explanatory mixed methods design was used combining analysis of use and program activity logs; program reports; and focus groups with CHWs, health care professionals, and program implementers. Quantitative analysis of use logs (March 2021 to September 2023) compared adoption over time by using descriptive statistics, CIs, and chi-square tests. Qualitative data came from the reanalysis of previous focus group transcripts and program reports and from a new focus group with program implementers. Reflexive thematic analysis was used to interpret how CHWs and implementers perceived and used the tool, and findings were integrated to explain quantitative trends. RESULTS Use of UpToDate was modest and declined over time. Monthly active use among CHWs and midwives fell substantially from 3.57% (97/2720 person-months) in 2021 to 1.07% (37/3456) in 2022 and remained low at 1.50% (39/2592) up to 2023, with markedly higher engagement in the rural site than in the remote site. Peaks in use coincided with program activities, whereas prolonged troughs followed typhoons, power outages, and other disruptions. Log data showed that users primarily consulted patient education articles rather than clinician-oriented decision tools. Qualitative analyses revealed that CHWs appropriated UpToDate as a learning aid and source of professional credibility. Structural shocks, heavy workloads, language barriers, and limited device access constrained individual use, and communal practices (shared devices and learning activities) meant that meaningful engagement often went unrecorded in vendor metrics. CONCLUSIONS Our findings show that acceptability does not guarantee sustained use and that adoption cannot be captured fully by log-in counts. UpToDate’s value for CHWs lay in how it was domesticated as a tool for building capacity and professional credibility, not in its intended function as a decision aid used at the point of care. Therefore, evaluations of digital health tools should incorporate indicators of learning and social capital alongside use metrics. Policymakers should recognize that infrastructural fragility and communal adaptation shape digital health uptake. Embedding tools into ongoing training and peer learning structures, providing offline and multilingual support, and investing in resilience planning will be crucial for meaningful scale-up and sustainability.
- Open Access
- 7 August 2024
- Published by BMJ in BMJ Health & Care Informatics
- Vol. 31 (1) , e100837
Perspectives on telemedicine across urban, rural and remote areas in the Philippines during the COVID-19 pandemic
Objectives: This study explored attitudes, subjective norms, and perceived behavioural control of participants across urban, rural and remote settings and examined intention-to-use telemedicine (defined in this study as remote patient–clinician consultations) during the COVID-19 pandemic. Methods: This is a cross-sectional study. 12 focus group discussions were conducted with 60 diverse telemedicine user and non-user participants across 3 study settings. Analysis of responses was done to understand the attitudes, norms and perceived behavioural control of participants. This explored the relationship between the aforementioned factors and intention to use. Results: Both users and non-users of telemedicine relayed that the benefits of telemedicine include protection from COVID-19 exposure, decreased out-of-pocket expenses and better work–life balance. Both groups also relayed perceived barriers to telemedicine. Users from the urban site relayed that the lack of preferred physicians discouraged use. Users from the rural and remote sites were concerned about spending on resources (ie, compatible smartphones) to access telemedicine. Non-users from all three sites mentioned that they would not try telemedicine if they felt overwhelmed prior to access. Discussion: First-hand experiences, peer promotions, and maximising resource support instil hope that telemedicine can help people gain more access to healthcare. However, utilisation will remain low if patients feel overwhelmed by the behavioural modifications and material resources needed to access telemedicine. Boosting infrastructure must come with improving confidence and trust among people. Conclusion: Sustainable access beyond the pandemic requires an understanding of factors that prevent usage. Sufficient investment in infrastructure and other related resources is needed if telemedicine will be used to address inequities in healthcare access, especially in rural and remote areas.
- 7 August 2024
- Published by BMJ in BMJ Health & Care Informatics
- Vol. 31 (1) , e100837
Open AccessPerspectives on telemedicine across urban, rural and remote areas in the Philippines during the COVID-19 pandemic
Objectives: This study explored attitudes, subjective norms, and perceived behavioural control of participants across urban, rural and remote settings and examined intention-to-use telemedicine (defined in this study as remote patient–clinician consultations) during the COVID-19 pandemic. Methods: This is a cross-sectional study. 12 focus group discussions were conducted with 60 diverse telemedicine user and non-user participants across 3 study settings. Analysis of responses was done to understand the attitudes, norms and perceived behavioural control of participants. This explored the relationship between the aforementioned factors and intention to use. Results: Both users and non-users of telemedicine relayed that the benefits of telemedicine include protection from COVID-19 exposure, decreased out-of-pocket expenses and better work–life balance. Both groups also relayed perceived barriers to telemedicine. Users from the urban site relayed that the lack of preferred physicians discouraged use. Users from the rural and remote sites were concerned about spending on resources (ie, compatible smartphones) to access telemedicine. Non-users from all three sites mentioned that they would not try telemedicine if they felt overwhelmed prior to access. Discussion: First-hand experiences, peer promotions, and maximising resource support instil hope that telemedicine can help people gain more access to healthcare. However, utilisation will remain low if patients feel overwhelmed by the behavioural modifications and material resources needed to access telemedicine. Boosting infrastructure must come with improving confidence and trust among people. Conclusion: Sustainable access beyond the pandemic requires an understanding of factors that prevent usage. Sufficient investment in infrastructure and other related resources is needed if telemedicine will be used to address inequities in healthcare access, especially in rural and remote areas.
- 28 December 2021
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 8 (8) , 899-908
The cost implications of a polypill for primary prevention in the TIPS-3 trial
Aims: The International Polycap Study 3 (TIPS-3) trial demonstrated that a polypill containing cholesterol- and multiple blood-pressure-lowering drugs reduces cardiovascular events by 20% compared with placebo in people without cardiovascular disease. The polypill plus aspirin led to a 31% relative risk reduction in cardiovascular disease events compared with double placebo. We report regional variations in costs and affordability of a polypill based on the TIPS-3 trial. Methods and results: Countries were categorized using World Bank economic groups: lower-middle-income, upper-middle-income, and high-income countries. Country-specific costs were obtained for hospitalization events, procedures, and non-study medications (2019 US dollars). Polypill price was based on the cheapest equivalent substitute (CES) for each component. For the polypill vs. placebo, the difference in cost over the 4.6 years of the trial was $291 [95% confidence interval (CI): $243–339] per participant in lower-middle-income countries, $1068 (95% CI: $992–1144) in upper-middle-income countries, and $48 (95% CI: −$271 to $367) in high-income countries. Results were similar for the polypill plus aspirin vs. a double placebo. In both cases, the polypill was affordable in all groups using monthly household capacity to pay or a threshold of 4% of the gross national income per capita. Conclusion: The use of a polypill (CES) in TIPS-3 increases costs in lower-middle-income countries and upper-middle-income countries but is affordable in countries at various economic levels and is cost neutral (dominant) in high-income countries.
- 28 December 2021
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 8 (8) , 899-908
The cost implications of a polypill for primary prevention in the TIPS-3 trial
Aims: The International Polycap Study 3 (TIPS-3) trial demonstrated that a polypill containing cholesterol- and multiple blood-pressure-lowering drugs reduces cardiovascular events by 20% compared with placebo in people without cardiovascular disease. The polypill plus aspirin led to a 31% relative risk reduction in cardiovascular disease events compared with double placebo. We report regional variations in costs and affordability of a polypill based on the TIPS-3 trial. Methods and results: Countries were categorized using World Bank economic groups: lower-middle-income, upper-middle-income, and high-income countries. Country-specific costs were obtained for hospitalization events, procedures, and non-study medications (2019 US dollars). Polypill price was based on the cheapest equivalent substitute (CES) for each component. For the polypill vs. placebo, the difference in cost over the 4.6 years of the trial was $291 [95% confidence interval (CI): $243–339] per participant in lower-middle-income countries, $1068 (95% CI: $992–1144) in upper-middle-income countries, and $48 (95% CI: −$271 to $367) in high-income countries. Results were similar for the polypill plus aspirin vs. a double placebo. In both cases, the polypill was affordable in all groups using monthly household capacity to pay or a threshold of 4% of the gross national income per capita. Conclusion: The use of a polypill (CES) in TIPS-3 increases costs in lower-middle-income countries and upper-middle-income countries but is affordable in countries at various economic levels and is cost neutral (dominant) in high-income countries.
- Open Access
- 12 August 2021
- Published by JMIR Publications Inc. in JMIR Cardio
- Vol. 5 (2) , e23464
A Patient Decision Aid for Anticoagulation Therapy in Patients With Nonvalvular Atrial Fibrillation: Development and Pilot Study
Background: Atrial fibrillation (AF) is one of the most common predisposing factors for ischemic stroke worldwide. Because of this, patients with AF are prescribed anticoagulant medications to decrease the risk. The availability of different options for oral anticoagulation makes it difficult for some patients to decide a preferred choice of medication. Clinical guidelines often recommend enhancing the decision-making process of patients by increasing their involvement in health decisions. In particular, the use of patient decision aids (PDAs) in patients with AF was associated with increased knowledge and increased likelihood of making a choice. However, the majority of available PDAs are from Western countries. Objective: We aimed to develop and pilot test a PDA to help patients with nonvalvular AF choose an oral anticoagulant for stroke prevention in the local setting. Outcomes were (1) reduction in patient decisional conflict, (2) improvement in patient knowledge, and (3) patient and physician acceptability. Methods: We followed the International Patient Decision Aid Standards (IPDAS) to develop a mobile app–based PDA for anticoagulation therapy in patients with nonvalvular AF. Focus group discussions identified decisional needs, which were subsequently incorporated into the PDA to compare choices for anticoagulation. Based on recommendations, the prototype PDA was rendered by at least 30 patients and 30 physicians. Decisional conflict and patient knowledge were tested before and after the PDA was implemented. Patient acceptability and physician acceptability were measured after each encounter. Results: Anticoagulant options were compared by the PDA using three factors that were identified (impact on stroke and bleeding risk, and price). The comparisons were presented as tables and graphs. The prototype PDA was rendered by 30 doctors and 37 patients for pilot testing. The mean duration of the encounters was 15 minutes. The decisional conflict score reduced by 35 points (100-point scale; P<.001). The AF knowledge score improved from 10 to 15 (P<.001). The PDA was acceptable for both patients and doctors. Conclusions: Our study showed that an app-based PDA for anticoagulation therapy in patients with nonvalvular AF (1) reduced patient decisional conflict, (2) improved patient knowledge, and (3) was acceptable to patients and physicians. A PDA is potentially acceptable and useful in our setting. A randomized controlled trial is warranted to test its effectiveness compared to usual care. PDAs for other conditions should also be developed.
- 12 August 2021
- Published by JMIR Publications Inc. in JMIR Cardio
- Vol. 5 (2) , e23464
Open AccessA Patient Decision Aid for Anticoagulation Therapy in Patients With Nonvalvular Atrial Fibrillation: Development and Pilot Study
Background: Atrial fibrillation (AF) is one of the most common predisposing factors for ischemic stroke worldwide. Because of this, patients with AF are prescribed anticoagulant medications to decrease the risk. The availability of different options for oral anticoagulation makes it difficult for some patients to decide a preferred choice of medication. Clinical guidelines often recommend enhancing the decision-making process of patients by increasing their involvement in health decisions. In particular, the use of patient decision aids (PDAs) in patients with AF was associated with increased knowledge and increased likelihood of making a choice. However, the majority of available PDAs are from Western countries. Objective: We aimed to develop and pilot test a PDA to help patients with nonvalvular AF choose an oral anticoagulant for stroke prevention in the local setting. Outcomes were (1) reduction in patient decisional conflict, (2) improvement in patient knowledge, and (3) patient and physician acceptability. Methods: We followed the International Patient Decision Aid Standards (IPDAS) to develop a mobile app–based PDA for anticoagulation therapy in patients with nonvalvular AF. Focus group discussions identified decisional needs, which were subsequently incorporated into the PDA to compare choices for anticoagulation. Based on recommendations, the prototype PDA was rendered by at least 30 patients and 30 physicians. Decisional conflict and patient knowledge were tested before and after the PDA was implemented. Patient acceptability and physician acceptability were measured after each encounter. Results: Anticoagulant options were compared by the PDA using three factors that were identified (impact on stroke and bleeding risk, and price). The comparisons were presented as tables and graphs. The prototype PDA was rendered by 30 doctors and 37 patients for pilot testing. The mean duration of the encounters was 15 minutes. The decisional conflict score reduced by 35 points (100-point scale; P<.001). The AF knowledge score improved from 10 to 15 (P<.001). The PDA was acceptable for both patients and doctors. Conclusions: Our study showed that an app-based PDA for anticoagulation therapy in patients with nonvalvular AF (1) reduced patient decisional conflict, (2) improved patient knowledge, and (3) was acceptable to patients and physicians. A PDA is potentially acceptable and useful in our setting. A randomized controlled trial is warranted to test its effectiveness compared to usual care. PDAs for other conditions should also be developed.
- Open Access
- 13 August 2020
- Published by JMIR Publications Inc. in JMIR Preprints
A Patient Decision Aid for Anticoagulation Therapy in Patients With Nonvalvular Atrial Fibrillation: Development and Pilot Study (Preprint)
BACKGROUND Atrial fibrillation (AF) is one of the most common predisposing factors for ischemic stroke worldwide. Because of this, patients with AF are prescribed anticoagulant medications to decrease the risk. The availability of different options for oral anticoagulation makes it difficult for some patients to decide a preferred choice of medication. Clinical guidelines often recommend enhancing the decision-making process of patients by increasing their involvement in health decisions. In particular, the use of patient decision aids (PDAs) in patients with AF was associated with increased knowledge and increased likelihood of making a choice. However, the majority of available PDAs is from Western countries. OBJECTIVE We aimed to develop and pilot test a PDA to help patients with nonvalvular AF choose an oral anticoagulant for stroke prevention in the local setting. Outcomes were (1) reduction in patient decisional conflict, (2) improvement in patient knowledge, and (3) patient and physician acceptability. METHODS We followed the International Patient Decision Aid Standards (IPDAS) to develop a mobile app–based PDA for anticoagulation therapy in patients with nonvalvular AF. Focus group discussions identified decisional needs, which were subsequently incorporated into the PDA to compare choices for anticoagulation. Based on recommendations, the prototype PDA was rendered by at least 30 patients and 30 physicians. Decisional conflict and patient knowledge were tested before and after the PDA was implemented. Patient acceptability and physician acceptability were measured after each encounter. RESULTS Anticoagulant options were compared by the PDA using three factors that were identified (impact on stroke and bleeding risk, and price). The comparisons were presented as tables and graphs. The prototype PDA was rendered by 30 doctors and 37 patients for pilot testing. The mean duration of the encounters was 15 minutes. The decisional conflict score reduced by 35 points (100-point scale; P<.001). The AF knowledge score improved from 10 to 15 (P<.001). The PDA was acceptable for both patients and doctors. CONCLUSIONS Our study showed that an app-based PDA for anticoagulation therapy in patients with nonvalvular AF (1) reduced patient decisional conflict, (2) improved patient knowledge, and (3) was acceptable to patients and physicians. A PDA is potentially acceptable and useful in our setting. A randomized controlled trial is warranted to test its effectiveness compared to usual care. PDAs for other conditions should also be developed.
- 13 August 2020
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessA Patient Decision Aid for Anticoagulation Therapy in Patients With Nonvalvular Atrial Fibrillation: Development and Pilot Study (Preprint)
BACKGROUND Atrial fibrillation (AF) is one of the most common predisposing factors for ischemic stroke worldwide. Because of this, patients with AF are prescribed anticoagulant medications to decrease the risk. The availability of different options for oral anticoagulation makes it difficult for some patients to decide a preferred choice of medication. Clinical guidelines often recommend enhancing the decision-making process of patients by increasing their involvement in health decisions. In particular, the use of patient decision aids (PDAs) in patients with AF was associated with increased knowledge and increased likelihood of making a choice. However, the majority of available PDAs is from Western countries. OBJECTIVE We aimed to develop and pilot test a PDA to help patients with nonvalvular AF choose an oral anticoagulant for stroke prevention in the local setting. Outcomes were (1) reduction in patient decisional conflict, (2) improvement in patient knowledge, and (3) patient and physician acceptability. METHODS We followed the International Patient Decision Aid Standards (IPDAS) to develop a mobile app–based PDA for anticoagulation therapy in patients with nonvalvular AF. Focus group discussions identified decisional needs, which were subsequently incorporated into the PDA to compare choices for anticoagulation. Based on recommendations, the prototype PDA was rendered by at least 30 patients and 30 physicians. Decisional conflict and patient knowledge were tested before and after the PDA was implemented. Patient acceptability and physician acceptability were measured after each encounter. RESULTS Anticoagulant options were compared by the PDA using three factors that were identified (impact on stroke and bleeding risk, and price). The comparisons were presented as tables and graphs. The prototype PDA was rendered by 30 doctors and 37 patients for pilot testing. The mean duration of the encounters was 15 minutes. The decisional conflict score reduced by 35 points (100-point scale; P<.001). The AF knowledge score improved from 10 to 15 (P<.001). The PDA was acceptable for both patients and doctors. CONCLUSIONS Our study showed that an app-based PDA for anticoagulation therapy in patients with nonvalvular AF (1) reduced patient decisional conflict, (2) improved patient knowledge, and (3) was acceptable to patients and physicians. A PDA is potentially acceptable and useful in our setting. A randomized controlled trial is warranted to test its effectiveness compared to usual care. PDAs for other conditions should also be developed.
- 22 January 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49 (Suppl_1)
Abstract 104: First Stroke Reduced 44 Percent by Well Tolerated Medications. Stroke Outcomes From the Heart Outcomes Prevention Evaluation 3 Study
Background: Most (75%) strokes are first strokes, and primary prevention is crucial for reducing the global burden of stroke The role of fixed-dose antihypertensive therapy and statin drugs for primary stroke prevention has not been adequately defined. Methods: Using a 2x2 factorial design, 12,705 participants from 21 countries with an intermediate risk of cardiovascular disease but without overt vascular disease were randomized to fixed-dose candesartan 16 mg plus hydrochlorothiazide (HCTZ) 12.5 mg daily or placebo and to rosuvastatin 10mg daily or placebo. Results: Mean age was 66 years, 46% were women, and 166 strokes occurred during a median follow-up of 5.6 years. Mean baseline blood pressure (BP) was 138/82 mmHg and the BP difference between the treatment groups during follow-up averaged 6.0/3.0 mmHg. Stroke was reduced by 20% (confidence interval [CI], 0.59-1.08; p =0.14) by candesartan/HCTZ and 30% (CI, 0.52-0.95) by rosuvastatin. In a pre-specified subgroup analysis, participants in the upper third of systolic BP (>143.5 mmHg) had stroke reduced by 42% (CI, 0.37-0.90, p =0.02). Rosuvatatin reduced all stroke by 30% (CI, 0.52-0.95; p =0.02); but considering hemorrhagic strokes: 15 among those assigned rosuvastatin vs. 12 with rosuvastatin-placebo. Those assigned both rosuvatatin and candesartan/HCTZ had stroke reduced by 44% ( CI, 0.36-0.87; p =0.009). Rates of permanent discontinuation did not differ significantly between active and placebo-assigned patients. Conclusions: Fixed-dose candesartan/HCTZ combined with low-dose rosuvastatin reduced first stroke by 44% in patients at intermediate risk of cardiovascular disease and was well-tolerated. Among those with systolic BP >143.5 mmHg, fixed-dose candesartan/HCTZ reduces first stroke by 42%,
- 22 January 2018
- Published by Wolters Kluwer Health in Stroke
- Vol. 49 (Suppl_1)
Abstract 104: First Stroke Reduced 44 Percent by Well Tolerated Medications. Stroke Outcomes From the Heart Outcomes Prevention Evaluation 3 Study
Background: Most (75%) strokes are first strokes, and primary prevention is crucial for reducing the global burden of stroke The role of fixed-dose antihypertensive therapy and statin drugs for primary stroke prevention has not been adequately defined. Methods: Using a 2x2 factorial design, 12,705 participants from 21 countries with an intermediate risk of cardiovascular disease but without overt vascular disease were randomized to fixed-dose candesartan 16 mg plus hydrochlorothiazide (HCTZ) 12.5 mg daily or placebo and to rosuvastatin 10mg daily or placebo. Results: Mean age was 66 years, 46% were women, and 166 strokes occurred during a median follow-up of 5.6 years. Mean baseline blood pressure (BP) was 138/82 mmHg and the BP difference between the treatment groups during follow-up averaged 6.0/3.0 mmHg. Stroke was reduced by 20% (confidence interval [CI], 0.59-1.08; p =0.14) by candesartan/HCTZ and 30% (CI, 0.52-0.95) by rosuvastatin. In a pre-specified subgroup analysis, participants in the upper third of systolic BP (>143.5 mmHg) had stroke reduced by 42% (CI, 0.37-0.90, p =0.02). Rosuvatatin reduced all stroke by 30% (CI, 0.52-0.95; p =0.02); but considering hemorrhagic strokes: 15 among those assigned rosuvastatin vs. 12 with rosuvastatin-placebo. Those assigned both rosuvatatin and candesartan/HCTZ had stroke reduced by 44% ( CI, 0.36-0.87; p =0.009). Rates of permanent discontinuation did not differ significantly between active and placebo-assigned patients. Conclusions: Fixed-dose candesartan/HCTZ combined with low-dose rosuvastatin reduced first stroke by 44% in patients at intermediate risk of cardiovascular disease and was well-tolerated. Among those with systolic BP >143.5 mmHg, fixed-dose candesartan/HCTZ reduces first stroke by 42%,